Benzinga Bulls And Bears: Nvidia, Palantir, Marvell Technology — And Markets Rallied In May Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.
Unusual volume stocks in Friday's session Discover the stocks with unexpected trading volume in today's session on the US markets.
These stocks are making the most noise in today's session. Stay updated with the latest market activity on Wednesday. Explore the most active stocks in today's session and stay informed about the stocks that are in the spotlight.
Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday? GSK and Spero ended a Phase 3 trial early meeting efficacy goals in cUTIs, positioning its treatment as the first oral carbapenem in the U.S.
GSK, Spero Therapeutics Stop Antibiotic Trial For Complicated Urinary Tract Infections Early After Positive Results, Retail’s Thrilled The early stop follows the trial meeting its primary endpoint of non-inferiority of Tebipenem HBr compared to an intravenous medicine in hospitalised adult patients with cUTI.
SPRO Stock Earnings: Spero Therapeutics Beats EPS, Beats Revenue for Q2 2024 SPRO stock results show that Spero Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
3 Micro-Cap Moonshots for Fearless Investors Investors should know the risks of micro-cap stocks before looking into these three high-potential companies with low prices.
SPRO Stock Earnings: Spero Therapeutics Misses EPS, Misses Revenue for Q1 2024 SPRO stock results show that Spero Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
